 --Received Gross Proceeds of 110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of 15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the closing of the previously announced 110 million private investment in public equity PIPE financing, as well as a newly executed PIPE financing for an additional 15 million in gross proceeds resulting from the sale of shares of its common stock at a price per share of 3.71. Gross proceeds from the two PIPE financings total 125 million, before deducting placement agent fees and offering expenses. The PIPE financings are supported by a consortium of high quality new and existing institutional investors with expertise in health care, including Redmile Group, Avidity Partners, EcoR1 Capital, BVF Partners L.P. and Versant Ventures. 